Esperion Therapeutics ESPR Collaboration revenue — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's collaboration revenue — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's collaboration revenue — total revenues?
- Esperion Therapeutics (ESPR) reported collaboration revenue — total revenues of $36.71M in Q1 2026.
- How has Esperion Therapeutics's collaboration revenue — total revenues changed year-over-year?
- Esperion Therapeutics's collaboration revenue — total revenues increased by 22.0% year-over-year, from $30.1M to $36.71M.
- What is the long-term trend for Esperion Therapeutics's collaboration revenue — total revenues?
- Over 4 years (2021 to 2025), Esperion Therapeutics's collaboration revenue — total revenues has grown at a 58.7% compound annual growth rate (CAGR), from $38.4M to $243.67M.
- What does collaboration revenue — total revenues mean?
- This metric represents revenue generated through strategic partnerships, licensing agreements, or joint development arrangements with other pharmaceutical or biotechnology entities. It captures income streams derived from milestone payments, royalties, or upfront fees associated with the commercialization and development of therapeutic assets. Monitoring this figure helps investors assess the company's ability to monetize its intellectual property and leverage external resources to expand market reach.